Celyad’s CAR T-cell Therapy Shows Promise in two Patients with Advanced Colorectal Cancer
Fresh data from the Phase one THINK clinical trial (NCT03018405) demonstrate that two metastatic colorectal cancer (mCRC) patients whose disease progressed following at least two prior therapies had stabilized the disease at a three-month follow-up after receiving the lowest dose level of Celyad’s NKR-2 CAR T-cell therapy. Read More